CytomX Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

CTMX$1.980.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Income

CONDENSED STATEMENTS OF OPERA TIONS AND COMPREHENSIVE INCOME (LOSS)

(in thousands, except share and per share data)

Three Months Ended · Six Months Ended
	June 30,		June 30,
	2026	2025	2026	2025
Revenues	$1,418	$18,658	$11,677	$69,575
Operating expenses:
Research and development	17,598	13,322	36,836	32,189
General and administrative	7,601	6,622	18,294	16,050
Total operating expenses	25,199	19,944	55,130	48,239
Income (loss) from operations	(23,781)	(1,286)	(43,453)	21,336
Interest income	3,157	1,178	4,647	2,133
Other income	18	17	11	28
Income (loss) before income taxes	(20,606)	(91)	(38,795)	23,497
Provision for income taxes	60	63	119	126
Net income (loss) attributable to common stockholders	(20,666)	(154)	(38,914)	23,371
Other comprehensive income (loss):
Unrealized gain (loss) on investments, net of tax	(298)	34	(307)	6
Total comprehensive income (loss)	$(20,964)	$(120)	$(39,221)	$23,377
Net income (loss) per share:
Basic	$(0.09)	$(0.00)	$(0.20)	$0.22
Diluted	$(0.09)	$(0.00)	$(0.20)	$0.21
Shares used to compute net income (loss) per share
Basic	218,939,423	129,075,546	198,221,312	108,214,373
Diluted	218,939,423	129,075,546	198,221,312	108,928,284

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.